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To the Editor
Melanoma is a considerable public health burden, with an estimated 76,690 new diagnoses
and 9,480 deaths from melanoma in the United States in 2013 alone (Howlader et al., 2013).
Multiplex families have pointed to important genetic factors for melanoma, including high-
penetrance risk loci such as CDKN2A or CDK4 (Gruber and Armstrong, 2006). In sporadic
disease, genome-wide association studies (GWAS) have also successfully identified at least
8 single nucleotide polymorphisms (SNPs) associated with melanoma (Gerstenblith et al.,
2010). Our study aimed to replicate these existing GWAS findings within the large
Population Architecture using Genomics and Epidemiology (PAGE) study in order to
further evaluate their association with melanoma.
In addition to genetic factors, other risk factors for melanoma include exposure to natural
and artificial ultraviolet radiation, larger numbers of nevi, pigmentation traits (light versus
dark hair, eye, and skin color), race/ethnicity (European versus non-European ancestry), skin
response to UV exposure (burn versus tan), older age, and male sex (Gruber and Armstrong,
2006). Anatomic location of melanoma also tends to vary by sex, arising most commonly on
the back, abdomen, and chest in males, and on the lower leg, hip, and thigh in females
(Gruber and Armstrong, 2006). Females also appear to have lower risk of metastases and
longer melanoma-specific survival than males (Joosse et al., 2011). As melanoma risk,
anatomic location, and survival have been shown to vary by sex, this study also aimed to
evaluate whether genetic associations with melanoma differed by sex as well.
To answer these questions, we evaluated 2,131 invasive melanoma cases and 20,353
melanoma-free controls from five study populations (Table S1). Three studies collaborated
through their participation in the PAGE study (Matise et al., 2011): the Multiethnic Cohort
(MEC); the Women's Health Initiative (WHI); and Epidemiological Architecture for Genes
Linked to Environment (EAGLE), accessing BioVU, the Vanderbilt biorepository linked to
de-identified electronic medical records. Two non-PAGE studies also contributed: the
Nurses' Health Study (NHS) and the Health Professionals Follow-up Study (HPFS).
Additional details for these studies are provided in the Supplementary Materials. All
analyses were performed using Stata version 13 (StataCorp LP, College Station, TX).
Study-specific logistic regression estimates evaluated the association between each SNP and
melanoma, coded additively for each copy of the purported risk allele. These results were
combined using fixed effect inverse-weighted meta-analysis to obtain overall effect
estimates. The association between a SNP and melanoma was considered statistically
significant if the Bonferroni-corrected p-value was below 0.006 (=0.05/8). In order to
evaluate for potential sex-specific genetic effects, we also evaluated the association between
each SNP and melanoma risk stratified by sex. We performed meta-regression to obtain p-
heterogeneity values for the difference between sex-specific regression estimates, using a
statistical significance threshold of p-heterogeneity<0.05. All participants were of European
ancestry. HPFS is a male-only study. Since NHS and WHI are female-only studies, the
overall analysis included roughly twice as many females as males (Table S1). Melanoma
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63 in controls), except for in EAGLE-BioVU where controls were younger (mean age 64 in
cases vs. 56 in controls).
We evaluated 8 SNPs previously identified by GWAS for an association with melanoma risk
(Bishop et al., 2009; Brown et al., 2008; Falchi et al., 2009; Fernandez et al., 2008;
Gerstenblith et al., 2010). These SNPs are in or near genes which are likely to be important
to melanoma pathways through their potential impact on melanogenesis (TYR, SLC45A2/
MATP, AFG3L1P/MC1R, PIGU/ASIP), cell cycle regulation (CDK10), cell growth and
apoptosis (PLA2G6), or tumor suppression (MTAP/CDKN2A). Results from the meta-
analyses across 3-5 studies showed 7 SNPs statistically significantly associated with
melanoma at Bonferroni-corrected levels (meta-analysis p<0.006), while the eighth SNP
was nominally significant (p=0.02; Table 1). All 8 SNPs showed an association in the same
direction and of similar magnitude as previously reported. Six of the 7 significant SNPs
showed a modest increase in melanoma risk (OR=1.17−1.55), while rs16891982 showed a
much larger effect (OR=3.11).
Sex-stratified analyses showed similar results, with 4 SNPs significantly associated with
melanoma in both male-only and female-only meta-analyses at Bonferroni-corrected levels,
and 3 SNPs nominally associated in each (meta-analysis p<0.05; Table S2). Only one of
these SNPs, rs16891982, showed a potential difference in effect by sex (p-
heterogeneity=0.02), with a stronger association in males (OR=5.50, 95% CI: 2.94–10.28)
than females (OR=2.37, 95% CI: 1.69–3.31; Table 2, Figure S1). This non-synonymous
SNP in the SLC45A2 gene has previously been associated with melanoma (Duffy et al.,
2010; Fernandez et al., 2008; Guedj et al., 2008) and pigmentation traits such as skin and
hair color (Stokowski et al., 2007). Also known as MATP, this gene encodes an ion
transporter protein in the melanosome. Ion and small molecule transport is functionally
important to melanogenesis and the pigmentation pathway (Scherer and Kumar, 2010), with
ion exchange predicted to impact melanogenesis by playing an important role in regulating
melanosome pH levels (Kondo and Hearing, 2011).
Providing biological plausibility for a potential sex difference in effect at this SNP is
evidence that skin pigmentation processes can be up- or down-regulated by sex hormones.
In a recent study of the hyperpigmentation condition melasma, findings supported the role of
several ion transporters, including SLC26A3, in the estrogen-induced expression of
tyrosinase (Kim et al., 2012). In another study, androgens were shown to have an inhibitory
effect on tyrosinase activity (Tadokoro et al., 2003). Tyrosinase is considered the rate-
limiting enzyme in melanin synthesis, and regulation of its activity can influence skin
pigmentation through the levels of eumelanin and phenomelanin produced (Kondo and
Hearing, 2011). Importantly, both tyrosinase levels and tyrosinase activity have also been
associated with rs16891982 genotype (Cook et al., 2009). As males and females differ in
their circulating levels of sex hormones, it is possible that these hormones impact ion
exchange or tyrosinase activity in a way that modifies the effect of this SLC45A2 variant on
melanoma risk, perhaps through alterations to melanogenesis or skin pigmentation.
Interestingly, sex differences in the genetic effect of solute carrier genes have also been seen
for other phenotypes, such as LYPLAL1/SLC30A10 with waist-hip ratio (Randall et al.,
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t2013). Further research is needed to evaluate these potential sex differences in genetic
contributions to melanoma risk.
This study was strengthened by the collaboration of five large studies, which provide sizable
samples to evaluate the melanoma GWAS SNP association with melanoma. Limitations
included two SNPs that were not available in HPFS and NHS (rs16891982 and rs910873),
though both still replicated. An additional limitation is that we were unable to test whether
some of our findings are independently associated with melanoma, or are due to an
association with pigmentation characteristics. Additional work will be needed to explore the
relationships between these genetic variants, pigmentation characteristics, and melanoma.
In summary, this large meta-analysis of five studies successfully replicated seven of eight
previous melanoma findings, with the eighth SNP still showing a suggestive effect in the
expected direction. Additionally, we observed potential differences in effect by sex for SNP
rs16891982 in SLC45A2, with a larger effect in males than females. This study reinforces
previous evidence that these genetic variants are important for melanoma risk, and for one
SNP provides suggestive evidence for a potential sex difference in effect. These results
implicate a complex interaction between genetic variants, ion transport, hormones, and
pigmentation on melanoma etiology, and demonstrate the potential utility of evaluating sex-
specific associations to further elucidate these relationships.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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